Literature DB >> 6659014

Carbamazepine--erythromycin interaction leading to carbamazepine toxicity in four epileptic children.

R Hedrick, F Williams, R Morin, W A Lamb, J C Cate.   

Abstract

We report four cases of carbamazepine toxicity in children associated with the concurrent administration of erythromycin. They all developed clinical toxicity (ataxia, dizziness, nausea, and vomiting) when erythromycin administration was begun; symptoms disappeared after erythromycin was discontinued. Serum carbamazepine levels were measured before, during, and, in most cases, after the toxic episodes. In all cases, there was a sharp increase in carbamazepine concentration after erythromycin therapy was begun and a rapid fall once erythromycin was discontinued. Our data support the previous suggestion that erythromycin interferes with the liver microsomal metabolism of carbamazepine with a subsequent increase in blood levels of the drug.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6659014     DOI: 10.1097/00007691-198312000-00005

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  13 in total

Review 1.  Treatment of concomitant illnesses in patients receiving anticonvulsants: drug interactions of clinical significance.

Authors:  P Loiseau
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

Review 2.  Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.

Authors:  E Spina; F Pisani; E Perucca
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

3.  Therapeutic drug monitoring.

Authors:  N Buchanan
Journal:  Indian J Pediatr       Date:  1986 Mar-Apr       Impact factor: 1.967

4.  Effect of febrile illness and its treatment on anticonvulsant levels in children.

Authors:  K J Goulden
Journal:  CMAJ       Date:  1986-06-15       Impact factor: 8.262

Review 5.  Antiepileptic drug toxicity: definition and mechanism of action.

Authors:  E Beghi; R Di Mascio
Journal:  Ital J Neurol Sci       Date:  1986-04

Review 6.  Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update.

Authors:  L Bertilsson; T Tomson
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

Review 8.  Carbamazepine overdose. Features of 33 cases.

Authors:  J F Seymour
Journal:  Drug Saf       Date:  1993-01       Impact factor: 5.606

Review 9.  Macrolide antibacterials. Drug interactions of clinical significance.

Authors:  N A von Rosensteil; D Adam
Journal:  Drug Saf       Date:  1995-08       Impact factor: 5.606

10.  Inhibition by erythromycin of the conversion of carbamazepine to its active 10,11-epoxide metabolite.

Authors:  N Barzaghi; G Gatti; F Crema; M Monteleone; C Amione; L Leone; E Perucca
Journal:  Br J Clin Pharmacol       Date:  1987-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.